Biopharma Daily Stock Updates - 02/05/21

$XBI $166.78 +2% 📈


$TGTX +12% UKINIQ FDA approval for adult patients with relapsed or refractory marginal zone lymphoma after at least one prior anti-CD20 based regimen. source

$SPRO +5% Phase 2a put on clinical hold following animal toxicology data. source

$AZN -1% Phase 3 trial did not meet primary/secondary endpoints. source


$ORTX +19% $150 Million Strategic Financing. source

$RYTM +4% Prices offering at $30/share. source


*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Big Movers™ is a trademark of Amp Biotech Research, LLC

©2021 by Biopharm IQ. Website by Awaken Studio.